Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer.

Under carefully defined conditions, fluorination can improve potency, stability and safety, and other critical drug attributes.

ET on Seeking Alpha About Trillium Therapeutics Trillium is … Corporate Presentation January 2017 This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future... | January 25, 2017 CAMBRIDGE, Mass., July 06, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (TSX:TRIL) (the "Corporation"), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced the voting results from its Annual and Special Meeting of Shareholders (the "Meeting") held on June 30, 2020. The results of the director elections were as follows: About Trillium Therapeutics. Trillium Therapeutics to Present Data on CD47 Blocker TTI-622 in Advanced Relapsed or Refractory Lymphoma at the ASCO20 Virtual Scientific Program Published: May 13, …

Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. We employ biologic and small molecule-based approaches that enhance the ability of the patient’s own immune system to detect and destroy cancer cells. A copy of the poster will also be available on the Events and Presentations page of Trillium’s website. View this Presentation (PDF) Corporate Presentation April 2020.

Presentations. 100 Cambridgepark Drive, Suite 510 Cambridge, MA 02140 USA Tel: +1 857.412.7029

This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events.
Trillium Therapeutics (TRIL) Investor Presentation - Slideshow Trillium Therapeutics (TRIL) Investor Presentation - Slideshow May. A live audio webcast of the H.C. Wainwright 21 st Annual Global Investment Conference presentation will be available under the investor relations section of Trillium’s website at www.trilliumtherapeutics.com. Trillium Therapeutics Inc. Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. 29, 2020 at 5:24 p.m.

Trillium Therapeutics (TRIL) Investor Presentation - Slideshow Trillium Therapeutics (TRIL) Investor Presentation - Slideshow May.

Trillium is employing our medicinal chemistry expertise which includes a proprietary platform that uses fluorine-based chemistry to yield new chemical entities.

Trillium Therapeutics to Present Data on CD47 Blocker TTI-622 in Advanced Relapsed or Refractory Lymphoma at the ASCO20 Virtual Scientific Program Published: May 13, … The company's lead program, TTI-621, is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1).